01Biologics & Protein Engineering
Recombinant antibody-based therapeutics — the fastest-growing class of drugs — built on Toronto's antibody discovery and commercialization expertise.
Research
Convergent science, from molecules to medicine
PRiME unites world-class investigators across the University of Toronto, its affiliated hospitals, and global academic and industry partners to address unmet needs in drug discovery, delivery, diagnostics, and disease biology — working at the convergence of science, medicine, and engineering.
Research areas
Six convergent areas of discovery
01
02Nanomedicine & Biomaterials
Nanomaterial agents for gene therapy and targeted delivery that concentrate treatment where it's needed and minimize side effects.
03Precision Diagnostics
Molecular and cellular analysis that tailors treatment to disease subtype and stage — the right therapy for the right patient.
04Targeted Small Molecule Therapeutics
Molecular therapeutics for cancer and infectious disease, engineered to balance potency with tolerability.
05Biology-on-a-Chip
Microfluidic devices that model disease biology and enable ex vivo drug testing on a chip.
06High-Throughput Omics & Disease Biology
Genomics and proteomics at scale, paired with deep disease-biology expertise across cancer, metabolic disease, and inflammation.
Disease priorities
Three frontiers where precision matters most
Precision Aging
Decoding the biology of aging to keep people healthier for longer.
Precision Oncology
Matching cancer treatment to the molecular signature of each tumour.
Precision Women's Health
Closing long-standing gaps in research and care for women's health.
Bring your research into the PRiME network.
Members access fellowships, global collaborations, and interdisciplinary training across the University of Toronto and its hospitals.